By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
All News
Article
Article
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Article
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.
Article
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases, with many theoretically well-founded agents appearing to have failed in clinical trials as a result of inefficacy, problem with trial design and/or safety issues.
Richard Conway
Tweet
More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK
Janet Pope
Tweet
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/u9KkZrUKGo
Richard Conway
Tweet
Boers et al. GLORIA trial of long term 5mg pred in RA. Titled as "favourable balance of benefit and harm". I cannot agree. 24% increase adverse events, NNH 9, for DAS28 0.37 better at 1 year, and really no difference after that. @RheumNow #EULAR2022 OP0263 https://t.co/eO4f1CjH5q https://t.co/VyyZm1QvYy
Richard Conway
Tweet
Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5
Eric Dein
Tweet
#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors
⭐️118 pts w MSK complaints
76% w arthralgias/myalgias, 30% with inflammatory rheumatic features
Most grade 1/2, 2 grade 4 (myositis)
23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study
@RheumNow https://t.co/SINqmmjsLq
Richard Conway
Tweet
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
David Liew
Tweet
Was ORAL Surveillance really a surprise?
Let's look post-hoc at all the other tofacitinib RCTs (ph 1-3b/4 +LTE)
Cardiovascular risk-enriched pts were always in the same MACE ballpark with tofa
ORAL Surveillance was worse, but clues were always there
OP0264 #EULAR2022 @RheumNow https://t.co/rB5SwVX2oc
Richard Conway
Tweet
Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R
David Liew
Tweet
MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it?
Vigibase: MACE (really MI) & VTE signals there before the scare
Always chance regulatory warnings cause stimulated reporting
but signal here was clear before RCT-driven alerts
OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy
Video: Further Considerations of the ORAL Surveillance Study
Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022
https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis).
@RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Aurelie Najm
Tweet
Does MTX have an impact on UST-immunogenicity in PsA?
Post-hoc analysis from UST RCT in 110+ pts
No difference in ADA rates & concentrations between
MTX and non-MTX groups and
ADA not associated w/ decreased UST levels
POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT
Eric Dein
Tweet
Kimme Hydrich: There is no increased of "exceedingly rare" vaccination adverse effects in rheumatic patients
💉APLS is NOT a risk factor for thrombotic AEs with vaccination
#EULAR2022 @Rheumnow @rheum_covid
Richard Conway
Tweet
Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certolizumab). ORs suggest possible B-cell modulators and vedolizumab, not others. Geneticist rvw no pattern for B-cell agents. @RheumNow #EULAR2022 OP0129 https://t.co/nrj8MxjAri https://t.co/p6JkfjjtdH


